Refine by
T Cell Receptor Suppliers & Manufacturers
27 companies found
based inOxford, UNITED KINGDOM
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Professor Shisong Jiang – Recombinant Overlapping Peptides (ROP). These ...
In the image below the Recombinant Overlapping Peptide is the “Antigen” being presented to the T Cell Receptor (TCR). This then triggers the growth of T ...
based inRixensart, BELGIUM
CuraVac is a clinical-stage biotech company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines for the treatment of autoimmune diseases. The company was founded by a ...
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research ...
based inMadison, WISCONSIN (USA)
Promega products are used by life scientists who are asking fundamental questions about biological processes as well as by scientists who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics ...
based inSherman Oaks, CALIFORNIA (USA)
T-Cure is a clinical-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to bringing new targets and therapies to the T-Cell Receptor (TCR) field that have a high ...
based inNantes, FRANCE
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics ...
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes ...
based inKraków, POLAND
Ardigen, a world-leading AI CRO, stands at the forefront of enabling AI transformation for the biotech and pharmaceutical sectors. Our objective is to increase the probability of success in the drug development process. We utilize our advanced ...
Accelerate discovery and improve safety of TCR therapies using Artificial Intelligence. Following the unique opportunity for curing patients provided by the development of cell therapies (e.g. TCR discovery), Ardigen has set on the path to advance ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet ...
based inPhiladelphia, PENNSYLVANIA (USA)
A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases Cabaletta Bio seeks to employ its specifically targeted CAAR (Chimeric AutoAntibody Receptor) T ...
based inSeoul, SOUTH KOREA
NGS industries are rapidly evolving and our customers are in greater need of technical support in various research fields and markets. Just like a chameleon utilizing its colored pigments and crystals to adapt to its surroundings, we proactively ...
Immune Repertoire often represents an individual’s current immuno- logical status, whether healthy, vaccinated, diseased or infected. Only the high-throughput NGS analysis could comprehensively profile an individual’s immune repertoire. ...
based inMawson Lakes, AUSTRALIA
Carina Biotech is an Australian pre-clinical immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. CAR-T therapy is a revolutionary new treatment option that uses a ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
Chimeric Antigen Receptor T cells (CAR-T) are genetically engineered T cells that are modified to express an artificial T ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
CAR T-cell therapy has recently emerged as a revolutionary and potentially curative therapy for patients with certain hematologic malignancies, including refractory cancers. In 2017, two CAR T-cell therapies were approved by the FDA for the ...
based inShirley, NEW YORK (USA)
After decades of research and accumulation, Creative Biolabs has become a leader in the discovery and manufacturing of recombinant antibodies (rAbs), providing the most reliable and qualified services to customers in academia and industry around the ...
γδ T cells are a distinct subgroup of T cells containing T cell receptors (TCRs) γ and TCR δ chains. Compared to αβ ...
based inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
The chimeric T cell antigen receptor therapy, also known as CAR-T, is an immunotherapy that is innovating the treatment of hematological and solid tumors. This new technology is ...
based inNew Delhi, INDIA
Takara Bio companies provide kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. As a member of the Takara Bio Group, DSS Takara Bio India Private Ltd. is part of a company that holds ...
SARS-CoV-2 research is happening at breakneck speed, and scientists are trying to identify epitopes that could trigger an immune response to the virus, an important step in the development of novel vaccines. Takara Bio offers an array of innovative ...
based inBerlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
Tumor immunotherapy utilizes active or passive methods to provoke tumor-specific immune responses in the body, harnessing their inhibitory and cytotoxic functions against tumor cells. Characterized by its specificity, efficacy, and mitigation of ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a specific and serial ...